Entero Therapeutics, Inc. confirmed on October 28, 2025, that it is now in compliance with Nasdaq's stockholders’ equity requirement after addressing earlier deficits. The company reported a stockholders' equity of $2.5 million following a share exchange agreement dated September 30, 2025, but may face delisting if future compliance isn't maintained.